Publicly Funded R&D In EU Should Come With Conditions, Says Report
Conditions should be attached to the public funding of biomedical R&D in response to escalating prices of drugs developed with public money, a new report says.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.